16 results
Phase Ib: Estimate the MTD and the RP2D of the combination of AEB071 and MEK162 in patients with metastatic uveal melanoma. And to assess the preliminary anti-tumor activity of the combination of AEB071 and MEK162. To characterize the PK profiels of…
Assessment of late effects of radiotherapy in patients with ONSM.
To evaluate the use of the new generation OCT in detecting retinal and choroidal changes associated with pigmented tumors of the choroid; in particular, transformations of benign lesions into malignant melanomas.
Estimate the maximum tolerated dose (MTD) of AEB071 (dose escalation) and characterize the safety and tolerability of the MTD or recommended Phase 2 dose of AEB071 in patients with metastatic uveal melanoma (dose expansion).
To evaluate the safety and efficacy of the combination of RFA and Ipilimumab in patients with unresectable, pathologically confirmed hepatic metastases of uveal melanoma.
This study has been transitioned to CTIS with ID 2024-516922-70-00 check the CTIS register for the current data. Phase I• Primary objectives:o To study the safety and feasibility of AT with autologous MC2 TCR T cells, combined with epigenetic drug…
1. Assess the effect of Ru-106 brachytherapy applicators on tumor dimensions. 2. Assess the value of DWI and PWI as an early predictor of therapy response after Ru-106 brachytherapy in UM.
Primary objective1. Assess that FAF can visualize the irradiated retina effects at an early stage after Ru-106 brachytherapy and PBT. Secondary objective1. Assess if these FAF-images can be correlated to the treatment plan.2. Correlate the observed…
The specific aim of the current study is to investigate the impact of oncological treatment and multiple GA in Rb survivors and Rb risk carriers (8-35 years) on cognitive functioning, psychosocial functioning and HRQoL. Furthermore, psychological…
This study has been transitioned to CTIS with ID 2023-509451-14-00 check the CTIS register for the current data. Primary:Phase I: • To characterize the safety and tolerability and to identify the maximum tolerated dose (MTD) and/or recommended dose…
We aim to assess the stability of the ocular structures and tantalum clips during the complete PBT treatment, so no part of the tumour is missed during radiotherapy, to reduce the total burden for the patient.
With this study we aim to improve the current ocular MRI protocols and assess its additional value in the diagnosis and therapy planning of UM.1. Extend the current 7T MRI protocols to provide information to differentiate tumour types.2. Translate…
To characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of LXS196 as a single agent or LXS196 in combination with HDM201 in patients with metastatic uveal melanoma.
The primary objective is to compare the OS in patients treated with IMCgp100 monotherapy versus Investigator*s Choice in HLA-A*0201 positive patients with advanced UM with no prior treatment in the metastatic setting. The secondary objectives of the…
To study the safety of the adoptive transfer of autologous T cells modified with a Mart-1 specific TCR in advanced stage (uveal) melanoma patients with disease progression upon standard cancer therapy. In addition, the toxicity according to CTC…
The objectives of the study are the following: - To develop a treatment for uveal melanoma metastases. For this purpose, the following will be conducted:* To establish an European Biobank of (preferably matched) UM metastasis, primary tumor and…